Open Payments

The Moses H. Cone Memorial Hospital

Type
Teaching hospital
Where
GREENSBORO, NC
Medicare CCN
340091
Received
$2,158,833 in 546 records, 2020 ($115,988 general, $2,042,844 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment217$115,988
2020Research payment329$2,042,844

By company

CompanyRecordsAmountYears
Novartis Pharmaceuticals Corporation6$827,1382020
CSL Behring27$247,5042020
CVRx, Inc.9$232,3332020
Sensible Medical Innovations Ltd2$215,0002020
Linvatec Corporation1$91,4582020
Amgen Inc.11$65,4842020
Varian Medical Systems, Inc.4$61,9422020
Medtronic Vascular, Inc.12$59,5302020
SANOFI PASTEUR INC.2$55,4302020
Merck Sharp & Dohme LLC14$46,9032020
PFIZER INC.59$40,8002020
Abbott Laboratories13$29,3782020
Baxter Healthcare6$27,4402020
Gilead Sciences, Inc.21$26,0312020
LivaNova USA, Inc.3$25,7082020
Esperion Therapeutics, Inc.62$24,2102020
Regeneron Pharmaceuticals, Inc.10$20,2392020
BIOTRONIK INC.62$16,1802020
AstraZeneca UK Limited1$10,3502020
Surmodics, Inc.7$9,2282020
Tandem Diabetes Care, Inc.18$5,0002020
Genentech, Inc.3$4,3272020
E.R. Squibb & Sons, L.L.C.4$3,6102020
Siemens Medical Solutions USA, Inc.3$3,0422020
Aesculap, Inc.2$2,8762020
Edwards Lifesciences Corporation2$1,9752020
Boehringer Ingelheim Pharmaceuticals, Inc.1$1,0002020
Genentech USA, Inc.1$1,0002020
AstraZeneca Pharmaceuticals LP1$1,0002020
Boston Scientific Corporation1$9752020
Zimmer Biomet Holdings, Inc.175$6912020
Becton, Dickinson and Company1$5902020
Hill-Rom Company, Inc1$4372020
Olympus America Inc.1$172020

By nature of payment

NatureRecordsAmount
Research payment329$2,042,844
Grant2$92,433
Space rental or facility fees (teaching hospital only)13$10,700
Compensation for services other than consulting, including serving as faculty or as a speaker at a v20$8,000
Gift179$4,022
Consulting Fee2$790
Charitable Contribution1$42

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31Medtronic Vascular, Inc.$6,687Research paymentIn-kind items and servicesReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2020
2020-12-31Siemens Medical Solutions USA, Inc.$42Charitable ContributionIn-kind items and services2020
2020-12-31Zimmer Biomet Holdings, Inc.$32GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2020
2020-12-29Amgen Inc.$4,620Research paymentCash or cash equivalentRepatha Biological, Cardiology(GOULD): a Registry of High Cardiovascular Risk Subjects in the United States2020
2020-12-23Gilead Sciences, Inc.$725Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2020
2020-12-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-23Esperion Therapeutics, Inc.$75Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-17CSL Behring$123Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-12-16LivaNova USA, Inc.$9,750Research paymentCash or cash equivalentVNS Therapy Device, Cardiology/Vascular DiseasesANTHEM HFrEF2020
2020-12-15CSL Behring$35,220Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-12-15CSL Behring$1,350Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-12-11Esperion Therapeutics, Inc.$36Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-10Aesculap, Inc.$1,697GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$1,179GiftCash or cash equivalent2020
2020-12-10Regeneron Pharmaceuticals, Inc.$1,140Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA2020
2020-12-10Regeneron Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA2020
2020-12-10Regeneron Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA2020
2020-12-09Esperion Therapeutics, Inc.$40Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-12-07Baxter Healthcare$3,369Research paymentCash or cash equivalentFluid Systems - Research Devel Biological, Fluid SystemsPeripheral IntraVenous Analysis -PIVA- compared with intermittent pulmonary capillary wedge pressure -PCWP-- in patients2020
2020-12-03SANOFI PASTEUR INC.$16,100Research paymentCash or cash equivalentSTA00011 Stamaril Yellow Fever2020
2020-12-02PFIZER INC.$1,750Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-02PFIZER INC.$1,750Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-12-02LivaNova USA, Inc.$1,300Research paymentCash or cash equivalentVNS Therapy Device, Cardiology/Vascular DiseasesANTHEM HFrEF2020
2020-11-24Varian Medical Systems, Inc.$1,742Research paymentCash or cash equivalentRapid Arc Device, DevicesAuto-Segmentation - Cone Health2020
2020-11-24Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-11-23Genentech, Inc.$1,421Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2020
2020-11-19CSL Behring$689Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-11-19Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$343Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-19Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-11-18Gilead Sciences, Inc.$1,450Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2020
2020-11-18Gilead Sciences, Inc.$1,358Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita2020
2020-11-12CSL Behring$32,912Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-11-12CSL Behring$1,350Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-12PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-11-09Medtronic Vascular, Inc.$156Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2020
2020-11-09Medtronic Vascular, Inc.$156Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2020
2020-11-04Abbott Laboratories$414Research paymentCash or cash equivalentAmplatzer PFO Device, Cardiac Arrhythmias and Heart FailureAMPLATZER PFO Occluder Post Approval Study2020
2020-11-04Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-11-02Esperion Therapeutics, Inc.$107Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-10-28Abbott Laboratories$6,978Research paymentCash or cash equivalentNanostim leadless pacemaker Device, Cardiac Arrhythmias and Heart FailureSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2020
2020-10-28CVRx, Inc.$6,649Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2020
2020-10-28Abbott Laboratories$975Research paymentCash or cash equivalentXience V Coronary Stent System Device, Cardiac Arrhythmias and Heart FailureXIENCE 28 USA Study2020
2020-10-28Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-10-27CSL Behring$123Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-10-24Amgen Inc.$14,360Research paymentCash or cash equivalentRepatha Biological, CardiologyCardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS)2020
2020-10-22Surmodics, Inc.$1,390Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2020
2020-10-22Surmodics, Inc.$1,390Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2020
2020-10-21Gilead Sciences, Inc.$691Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2020
2020-10-20Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-10-20Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-10-20Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-10-20Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-10-20Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-10-19AstraZeneca UK Limited$10,350Research paymentCash or cash equivalentA Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo 2020
2020-10-14BIOTRONIK INC.$406Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$406Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$406Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$406Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-10-14Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$44Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$44Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$44Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-14BIOTRONIK INC.$44Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-10-13Medtronic Vascular, Inc.$334Space rental or facility fees (teaching hospital only)Cash or cash equivalentResolute Device, Stents2020
2020-10-13Medtronic Vascular, Inc.$333Space rental or facility fees (teaching hospital only)Cash or cash equivalentResolute Device, Stents2020
2020-10-13Medtronic Vascular, Inc.$333Space rental or facility fees (teaching hospital only)Cash or cash equivalentResolute Device, Stents2020
2020-10-09Amgen Inc.$925Research paymentIn-kind items and servicesRepatha Biological, CardiologyCardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS)2020
2020-10-08Regeneron Pharmaceuticals, Inc.$3,143Research paymentCash or cash equivalentPRALUENT Biological, CARDIOVASCULAR AND METABOLISMA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PA2020
2020-10-07Varian Medical Systems, Inc.$200Consulting FeeCash or cash equivalent2020
2020-10-06CSL Behring$17,711Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-10-06CSL Behring$750Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-10-01Genentech, Inc.$1,453Research paymentCash or cash equivalentHerceptin Biological, BioOncologyA PHASE III TRIAL IN ADJUVANT HER2 BC PTS2020
2020-10-01Edwards Lifesciences Corporation$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentEdwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves2020
2020-09-30Boehringer Ingelheim Pharmaceuticals, Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2020
2020-09-29Siemens Medical Solutions USA, Inc.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSOMATOM GO Device, CT and RO incl. Computed Tomography and Radiation Oncology2020
2020-09-24Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-23Gilead Sciences, Inc.$691Research paymentCash or cash equivalentBiktarvy Drug, HIVA Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena2020
2020-09-23Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$572Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22BIOTRONIK INC.$406Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$406Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22Esperion Therapeutics, Inc.$343Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$343Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$343Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$281Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$225Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22Esperion Therapeutics, Inc.$200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2020
2020-09-22BIOTRONIK INC.$44Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-22BIOTRONIK INC.$44Research paymentCash or cash equivalentOrsiro Device, Cardiology/Vascular DiseasesBIOFLOW-V2020
2020-09-18PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-09-18PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-09-18PFIZER INC.$1,000Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-09-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-09-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-09-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-09-18PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2020
2020-09-17Medtronic Vascular, Inc.$2,490Research paymentCash or cash equivalentReveal LINQ Device, Cardiac Diagnostics and MonitoringStroke AF2020
2020-09-14Becton, Dickinson and Company$590Consulting FeeCash or cash equivalent2020
2020-09-10CSL Behring$39,618Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-09-10CSL Behring$1,250Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-09-09Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 insulin pump Device, Endocrinology2020

The latest 200 records of 546.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Guilford CountyGreensboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.

MeasurePlace (city or town)
Greensboro, NC
County
Guilford County, NC
State
North Carolina
Population B01003301,198547,94010,730,404
Population, 2020 census P1299,035541,29910,439,388
Median age B0100234.337.539.1
Under 18 B0100121.7%22.0%21.8%
65 and over B0100114.4%15.9%17.2%
Households B11001123,984219,7184,282,345
Foreign born B0500212.7%11.8%9.1%
Median household income B19013$61,515$68,642$72,388
Median family income B19113$80,585$88,156$90,290
Per capita income B19301$37,531$39,376$41,385
Poverty rate B1700117.0%14.6%13.0%
Unemployment rate B230255.1%4.6%4.7%
Civilian labor force B23025158,568282,3625,336,863
Mean commute (minutes) B0801321.722.025.1
Bachelor's degree or higher B1500341.0%39.0%35.7%
Housing units B25001135,665238,0324,895,668
Owner-occupied B2500350.5%59.9%66.6%
Renters B2500349.5%40.1%33.4%
Median home value B25077$244,800$259,900$288,900
Median gross rent B25064$1,172$1,163$1,228
White, not Hispanic B0300238.1%46.0%60.0%
Black B0300241.0%33.5%20.0%
Hispanic or Latino B0300210.5%10.1%11.3%
Asian B030025.2%5.4%3.3%
American Indian and Alaska Native B030020.2%0.1%0.8%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.